TSXV:CLAS.H - Post by User
Post by
losingmyshirton Aug 22, 2021 11:07am
![](https://assets.stockhouse.com/kentico-cms/0340-00/images/Sprite.svg#id_Post_Views_Icon)
290 Views
Post# 33746051
Why has Kalytera never accomplished anything?
Why has Kalytera never accomplished anything? AS FAR AS BOB'S CONCERNED, HE IS ALWAYS ON YTHE RIGHT TRACK. IT ALL SOUNDS ROSY UNTIL THEY PULL THE PLUG AND MOVE ON.
“We are very encouraged by the results we are seeing,” stated Robert Farrell, President and CEO of Kalytera. “We did not anticipate that the results for the low dose cohort would be as positive as they were, and now the interim results for the medium dose cohort are even better. These results will leave little or no room for improvement with the high dose of 300 mg of CBD administered twice daily.”
The results of Study KAL-05 to date are in line with data from the two previous Phase 2a clinical studies that were completed by Dr. Moshe Yeshurun, Kalytera’s Chief Medical Officer, at the Institute of Hematology, Davidoff Center, Rabin Medical Center, Petah Tikva, Israel.
The results from the first of these previous clinical studies were published in Biology of Blood and Marrow Transplantation (Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study, M. Yeshurun et al. / Biology Blood Marrow Transplant 21 (2015) 1770 – 1775). The 48 patients in this study received daily doses of 150 mg of CBD administered twice daily for 7 days prior to their bone marrow transplant procedure and for 30 days after, and, as previously